Selective immunosuppressant medicines under a framework agreement
Outcome
This tender has been awarded. The award details are not published yet. Open tenders like this one are listed below.
- Place
- Catalonia, Spain
- Submission deadline
- Not available
- Contract value
- €1,301,435.44
- Official estimated contract value; the base tender budget is EUR 406,698.58 excluding VAT
- Contract period
- One year, with an option to extend for two more years.
- Published
- November 25, 2020
- Plataforma de serveis de contractació pública (Catalonia)
Overview
Badalona Serveis Assistencials formalized a call-off contract for selective immunosuppressant medicines under a framework agreement. The official publication gives a base budget of EUR 406,698.58 excluding VAT, an estimated contract value of EUR 1,301,435.44, a one-year term with a two-year extension option, and 12 awarded suppliers. The notice records formalization on 24 November 2020.
Information based on the public notice
Ask about this tender
What the buyer needs
The contract covers selective immunosuppressant medicines purchased under the existing framework agreement. The official Catalan publication identifies 12 awarded suppliers with separate amounts, a one-year initial duration and a two-year extension option.
- The procedure is negotiated without publication under an existing framework agreement.
Tender details
- Buyer
- Badalona Serveis Assistencials, SA
- Country
Spain
- Procedure
- Negotiated procedure without prior publication
- Classification
- Pharmaceutical products · CPV 33600000 · NUTS ES51
- Notice reference
- 6664789
- Base tender budget (excluding VAT)
- EUR 406,698.58
- Estimated contract value
- EUR 1,301,435.44
- Awarded suppliers
- 12: AMGEN EUROPE, BV: 28,705.59 EUR; PFIZER, SLU: 1,959.28 EUR; MERCK SHARP DOHME DE ESPAÑA, SA: 31,407.32 EUR; SANDOZ FARMACÉUTICA, SA: 102,765.00 EUR; BRISTOL-MYERS SQUIBB, SAU: 20,529.02 EUR; TAKEDA FARMACÉUTICA ESPAÑA, SA: 1,529.45 EUR; ROCHE FARMA, SAU: 11,055.20 EUR; UCB PHARMA, SA: 13,328.35 EUR; NOVARTIS FARMACÉUTICA, SA: 121,017.31 EUR; JANSSEN CILAG, SA: 45,146.32 EUR; LILLY, SA: 15,740.73 EUR; BIOGEN SPAIN, SL: 13,515.00 EUR
- Offers received
- 12
What to check in the tender documents
- The API does not provide a single aggregate award amount; the publication lists supplier-specific award amounts.
Original notice
Read the original description
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius
Official source: Plataforma de serveis de contractació pública (Catalonia) ↗
Notice updates
October 16, 2026 · Version 3
Summary and analysis updated
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius. Expedient CB BSA CSC F 4/18. Badalona Serveis Assistencials, SA. Procediment negociat sense publicitat; contracte de subministraments. Pressupost base: 406.698,58 EUR sense IVA; 422.966,52 EUR amb IVA (4%). Valor estimat del contracte: 1.301.435,44 EUR. Durada inicial: un any, amb opció de pròrroga de dos anys. Àmbit geogràfic: Catalunya. Codi CPV 33600000. Adjudicació: 9 de novembre de 2020. Formalització: 24 de novembre de 2020. La publicació enumera 12 empreses adjudicatàries i imports individuals: AMGEN EUROPE, BV — 28.705,59 EUR sense IVA; PFIZER, SLU — 1.959,28 EUR; MERCK SHARP & DOHME DE ESPAÑA, SA — 31.407,32 EUR; SANDOZ FARMACÉUTICA, SA — 102.765,00 EUR; BRISTOL-MYERS SQUIBB, SAU — 20.529,02 EUR; TAKEDA FARMACÉUTICA ESPAÑA, SA — 1.529,45 EUR; ROCHE FARMA, SAU — 11.055,20 EUR; UCB PHARMA, SA — 13.328,35 EUR; NOVARTIS FARMACÉUTICA, SA — 121.017,31 EUR; JANSSEN CILAG, SA — 45.146,32 EUR; LILLY, SA — 15.740,73 EUR; BIOGEN SPAIN, SL — 13.515,00 EUR.
October 16, 2026 · Version 2
Buyer updated · Classification updated · Contract period updated · Summary and analysis updated · Tender facts updated · Original notice updated · Deadline updated · Location updated · Source updated · Source notice details updated · Source references updated
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius. Expedient CB BSA CSC F 4/18. Badalona Serveis Assistencials, SA. Procediment negociat sense publicitat; contracte de subministraments. Pressupost base: 406.698,58 EUR sense IVA; 422.966,52 EUR amb IVA (4%). Valor estimat del contracte: 1.301.435,44 EUR. Durada inicial: un any, amb opció de pròrroga de dos anys. Àmbit geogràfic: Catalunya. Codi CPV 33600000. Adjudicació: 9 de novembre de 2020. Formalització: 24 de novembre de 2020. La publicació enumera 12 empreses adjudicatàries i imports individuals: AMGEN EUROPE, BV — 28.705,59 EUR sense IVA; PFIZER, SLU — 1.959,28 EUR; MERCK SHARP & DOHME DE ESPAÑA, SA — 31.407,32 EUR; SANDOZ FARMACÉUTICA, SA — 102.765,00 EUR; BRISTOL-MYERS SQUIBB, SAU — 20.529,02 EUR; TAKEDA FARMACÉUTICA ESPAÑA, SA — 1.529,45 EUR; ROCHE FARMA, SAU — 11.055,20 EUR; UCB PHARMA, SA — 13.328,35 EUR; NOVARTIS FARMACÉUTICA, SA — 121.017,31 EUR; JANSSEN CILAG, SA — 45.146,32 EUR; LILLY, SA — 15.740,73 EUR; BIOGEN SPAIN, SL — 13.515,00 EUR.
October 12, 2026 · Version 1
Published
Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius
titol: Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius descripcioPrestacio: Contracte basat de l'Acord Marc del Subministrament de medicaments d'inmunosupressors selectius pressupostLicitacioSenseIva: 406698.58 pressupostLicitacioAmbIva: 422966.52 valorEstimatContracte: 1301435.44 durada: {"esDurada": null, "anys": 1, "mesos": 0, "dies": 0, "iniciTermini": null, "fiTermini": null, "observacions": null} lots: [{"numeroLot": null, "compraInnovacio": false, "descripcioLot": null, "dataAdjudicacio": "2020-11-09T23:00:00.000Z", "dataFormalitzacioContracte": "2020-11-24T23:00:00.000Z", "importFormalitzacioAmbIva": 0.0, "numeroOfertesRebudes": 12, "identitatEmpresesLicitadores": null, "lotDesert": false, "empresesAdjudicataries": [{"denominacio": "AMGEN EUROPE, BV", "ambitGeografic": "Espanya", "importAmbIva": 29853.82, "importSenseIva": 28705.59}, {"denominacio": "PFIZER, SLU", "ambitGeografic": "Espanya", "importAmbIva": 2037.65, "importSenseIva": 1959.28}, {"denominacio": "MERCK SHARP DOHME DE ESPAÑA, SA", "ambitGeografic": "Espanya", "importAmbIva": 32663.62, "importSenseIva": 31407.32}, {"denominacio": "SANDOZ FARMACÉUTICA, SA", "ambitGeografic": "Espanya", "importAmbIva": 106875.6, "importSenseIva": 102765.0}, {"denominacio": "BRISTOL-MYERS SQUIBB, SAU", "ambitGeografic": "Espanya", "importAmbIva": 21350.19, "importSenseIva": 20529.02}, {"denominacio": "TAKEDA FARMACÉUTICA ESPAÑA, SA", "ambitGeografic": "Espanya", "importAmbIva": 1590.63, "importSenseIva": 1529.45}, {"denominacio": "ROCHE FARMA, SAU", "ambitGeografic": "Espanya", "importAmbIva": 11497.41, "importSenseIva": 11055.2}, {"denominacio": "UCB PHARMA, SA", "ambitGeografic": "Espanya", "importAmbIva": 13861.49, "importSenseIva": 13328.35}, {"denominacio": "NOVARTIS FARMACÉUTICA, SA", "ambitGeografic": "Espanya", "importAmbIva": 125858.0, "importSenseIva": 121017.31}, {"denominacio": "JANSSEN CILAG, SA", "ambitGeografic": "Espanya", "importAmbIva": 46952.17, "importSenseIva": 45146.32}, {"denominacio": "LILLY, SA", "ambitGeografic": "Espanya", "importAmbIva": 16370.35, "importSenseIva": 15740.73}, {"denominacio": "BIOGEN SPAIN, SL", "ambitGeografic": "Espanya", "importAmbIva": 14055.6, "importSenseIva": 13515.0}]}]
https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/awardnotice.pscp?reqCode=viewDcan&idDoc=72663332&lawType=3
Source retrieved: 2026-10-16T01:46:09.965684Z